# Autologous Endothelial Progenitor Cell Therapy for Reversal of Liver Cirrhosis

> **NCT03109236** · PHASE3 · UNKNOWN · sponsor: **National University Hospital, Singapore** · enrollment: 66 (estimated)

## Conditions studied

- End Stage Liver Disease

## Interventions

- **DRUG:** GCSF
- **PROCEDURE:** CD133 Cells Transplantation

## Key facts

- **NCT ID:** NCT03109236
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-08-24
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2021-01-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03109236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03109236, "Autologous Endothelial Progenitor Cell Therapy for Reversal of Liver Cirrhosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03109236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*